Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.

@article{Sattlecker2016LongitudinalPC,
  title={Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.},
  author={Martina Sattlecker and Mizanur R. Khondoker and Petroula Proitsi and Stephen E. Williams and Hilkka Soininen and Iwona Kloszewska and Patrizia Mecocci and Magda Tsolaki and Bruno Vellas and Simon Lovestone and Richard J. B. Dobson},
  journal={Journal of Alzheimer's disease : JAD},
  year={2016},
  volume={49 4},
  pages={
          1105-14
        }
}
Biomarkers of Alzheimer's disease (AD) progression are needed to support the development of urgently needed disease modifying drugs. We employed a SOMAscan assay for quantifying 1,001 proteins in blood samples from 90 AD subjects, 37 stable mild cognitive impaired (MCI) subjects, 39 MCI subjects converting to AD within a year and 69 controls at baseline and one year follow up. We used linear mixed effects models to identify proteins changing significantly over one year with the rate of… 
View on PubMed
discovery.ucl.ac.uk
27 Citations
Background Citations
4
Methods Citations
2

Figures and Tables from this paper

27 Citations

Citation Type

Citation Type

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
Blood-Derived Plasma Protein Biomarkers for Alzheimer’s Disease in Han Chinese
TLDR
It is suggested that a combination of eight plasma proteins can serve as a promising diagnostic biomarker for AD with high sensitivity and specificity in Han Chinese populations.
Blood-based molecular biomarkers for Alzheimer’s disease
TLDR
The literature on candidate blood tests for AD that could be implemented in primary care settings and used for the effective identification of individuals at increased risk of AD pathology, who could be referred for potential inclusion in clinical trials or future approved treatments following additional testing are summarized.
Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk
TLDR
A proteome-wide association study is reported that identifies 38 candidate proteins in nondemented older adults that are associated with future dementia risk, and pathway analysis of these proteins implicates immune, lipid, metabolic signaling and hemostasis pathways in dementia pathogenesis.
A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication
TLDR
The focus is primarily to identify a minimally invasive and hopefully cost-effective blood-based biomarker to reduce screen failure in clinical trials where participants have prodromal or even pre-clinical disease.
Proteomics as a reliable approach for discovery of blood-based Alzheimer’s disease biomarkers: A systematic review and meta-analysis
Genome and epigenome wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease risk
The levels of many blood proteins are associated with Alzheimer's disease or its pathological hallmarks. Elucidating the molecular factors that control circulating levels of these proteins may help…
Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence
Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline
Alterations in Alzheimer’s Disease-Associated Gene Expression in Severe Obstructive Sleep Apnea Patients
TLDR
Investigation of differential expressions of AD-associated genes in OSA patients without evident AD or dementia found inflammation may contribute to the onset of AD and physicians need to be aware of the potential occurrence of AD in patients with severe OSA.
...
1
2
3
...

References

SHOWING 1-10 OF 66 REFERENCES
Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
TLDR
Five inflammatory proteins associated with evidence of atrophy on MR imaging data particularly in whole brain, ventricular and entorhinal cortex measures and IL-10 were associated with both clinical and imaging evidence of severity of disease and might therefore have potential to act as biomarker of disease progression.
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
TLDR
Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B-type brain natriuretic peptide in patients with AD and mild cognitive impairment, supporting their usefulness as a screening tool.
Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression.
TLDR
Results show that the combination of imaging and cytokine biomarkers provides an improvement in prediction of MCI to AD conversion compared to either datatype alone, APOE genotype or clinical data and an accuracy of prediction that would have clinical utility.
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease
TLDR
The association of plasma CFH and A2M with hippocampal NAA/mI in this cohort of AD subjects suggests that these proteins may reflect disease progression in early AD, and warrant validation in large population-based datasets.
Blood-based protein biomarkers for diagnosis of Alzheimer disease.
TLDR
This study identified a panel of plasma biomarkers that distinguish individuals with AD from cognitively healthy control subjects with high sensitivity and specificity.
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.
TLDR
These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
TLDR
Blood‐based testing will most likely be the prerequisite to future sensitive screening of large populations at risk of AD and the baseline in a diagnostic flow approach to AD.
Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease.
TLDR
Immunohistochemical validation of the findings on brain tissue sections showed strong PZP expression in senile plaques and in microglial and glial cells in AD with only low expression in some scattered glia cells in controls.
Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
TLDR
Data from the Alzheimer's Disease Neuroimaging Initiative was used and the relationship between these variables and brain amyloid burden was explored, and the number of APOE ϵ 4 alleles and plasma apolipoprotein E level were found to contribute most to this model.
...
1
2
3
4
5
...